Full Press Release Details
BridgeBio Pharma LLC Signs Joint Collaboration Agreement With Cincinnati Children's To Accelerate Development Of Genetic Disease Therapeutics.
BBIO
BridgeBio Pharma LLC Signs Joint Collaboration Agreement With Cincinnati Children's To Accelerate Development Of Genetic Disease Therapeutics
Key Takeaway: BridgeBio Pharma LLC Signs Joint Collaboration Agreement With Cincinnati Children's To Accelerate Development Of Genetic Disease Therapeutics
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+41%
120-day peak, hindsight
Typical move
3.6%
average across 13 past catalysts
Cash runway
~30 mo
Minimal dilution risk
Lead asset
acoramidis
Phase 3 · Amyloidosis